Syntermed anticipates NeuroQ approval
A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the
A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the third quarter for the NeuroQ software, which rapidly and automatically quantifies more than 200 standardized regions of interest. It compares activity in those brain regions to regional activity values derived from a database of normal scans.
Can a Six-Minute MRI Facilitate Detection of Multiple Sclerosis?
May 23rd 2025Recognition of the central vein sign with a six-minute MRI demonstrated comparable sensitivity for multiple sclerosis (MS) detection in comparison to oligoclonal band (OCB) assessment, which requires lumbar puncture, according to newly published research.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
